Ocugen's Caribbean Approval Can't Outrun the 250 Million Share Question

Ocugen gained provisional Bahamas authorization for gene therapy OCU400, but shareholders adjourned a vote on 250 million new shares to October 5.

Ocugen has secured a preliminary green light in the Bahamas for its gene therapy candidate OCU400, a regulatory sidestep that gives the biotech a chance to gather real-world treatment experience while the slower approval machinery in the US and Europe grinds on. The Longevity and Regenerative Therapies Board granted both a provisional authorization and priority review status for the therapy, which targets retinitis pigmentosa. Under an expanded access program, Ocugen intends to treat its first patient within 90 days of receiving full clearance from the relevant board.

For a company developing novel therapies, such overseas initiatives offer a practical proving ground. They allow developers to accumulate hands-on clinical data in parallel with the lengthy authorization processes that govern the core markets. Whether a Caribbean regulatory shortcut can ease the structural anxieties weighing on shareholders is another matter entirely.

A Modest Market Reception

The market's response on Friday was tepid at best. The stock closed the trading week up 2.2% at EUR 0.9130, still a full 61% below its 52-week high. The muted reaction reflects where investor attention actually sits: not on pipeline milestones, but on the company's strained financing and capital structure.

That operational news has been arriving with some regularity. Roughly two weeks ago, the start of a Phase 3 trial for OCU410 marked another milestone that briefly lifted the shares. The science, in other words, keeps moving forward. The balance sheet question does not go away.

Shareholders Stall the Capital Increase

Investor reluctance came into plain view on Monday, when shareholders at a special meeting voted to adjourn a decision on creating 250,000,000 additional shares. Only 160,214,431 shares were represented, equal to 47.3% of the common stock outstanding as of the July 27, 2026 record date.

The adjournment motion itself passed with 124,584,658 votes in favor against 33,639,820 opposed, with 1,989,953 abstentions. That does not resolve anything — it merely postpones the reckoning. The reconvened extraordinary shareholders' meeting is set for October 5, 2026, at 8:00 a.m. ET, when the management request to raise authorized common stock by a quarter of a billion shares will be put to a vote once more.

For existing holders, the proposed expansion carries the threat of severe dilution. Confidence in management was already frayed: an insider sale by the CEO roughly a month ago caused considerable consternation among investors, and the share price has shed 20.7% since. Analysts reaffirmed their buy rating about two weeks ago, nudging the stock up 3.4% at the time, but that endorsement has done little to dispel the broader skepticism. Fear of a massive increase in the share count carries more weight than the judgment of market watchers.

The Biotech Dilemma in Full View

The standoff captures the classic bind of capital-intensive biotech: without fresh equity, expensive clinical research is difficult to finance through to market readiness, yet every new tranche threatens to dilute existing shareholders meaningfully. Treating rare eye diseases like retinitis pigmentosa remains a field of genuine scientific promise. But until Ocugen secures approval for its capital measures, even regulatory wins in the Bahamas offer only faint consolation for the stock.

The preliminary authorization shows OCU400 is making therapeutic progress. Yet as long as the sword of 250 million additional shares hangs over the company, any rally rests on shaky ground. October 5 will determine what price shareholders must pay to keep the research going. Until then, there is little to justify premature optimism.